on this page
Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with lenalidomide and tafasitamab under the National Health Act 1953, section 100 for patients with relapsed or refractory follicular lymphoma.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing lenalidomide and tafasitamab.
Section 100 - Highly Specialised Drugs
Lenalidomide
This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending either:
- an approved private hospital
- a public hospital.
This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital provider number with the authority application.
Section 100 - Efficient Funding of Chemotherapy
Tafasitamab
This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending either:
- an approved private hospital
- a public participating hospital
This item isn’t PBS-subsidised for public hospital in-patients.
Authority applications
Applying for initial treatment
Applications for initial authority approval to prescribe PBS-subsidised lenalidomide or tafasitamab to treat relapsed or refractory follicular lymphoma can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for continuing treatment
Applications for continuing authority approval to prescribe PBS-subsidised lenalidomide or tafasitamab to treat relapsed or refractory follicular lymphoma can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.